Q3 Earnings Estimate for Climb Bio Issued By William Blair

Key Points

• William Blair has projected Climb Bio's Q3 2025 earnings to be ($0.14) per share, maintaining an "Outperform" rating on the stock.
• Climb Bio's full-year earnings estimate is forecasted at ($1.57) per share, with a gradual increase in expected losses through FY2029.
• Despite mixed ratings from various analysts, the overall consensus for Climb Bio's stock is a "Buy," with a target price of $9.20.

Climb Bio, Inc. (NASDAQ:CLYM - Free Report) - Investment analysts at William Blair issued their Q3 2025 earnings estimates for shares of Climb Bio in a research report issued to clients and investors on Thursday, October 16th. William Blair analyst M. Phipps forecasts that the company will post earnings of ($0.14) per share for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Climb Bio's current full-year earnings is ($1.57) per share. William Blair also issued estimates for Climb Bio's Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.72) EPS, FY2026 earnings at ($0.73) EPS, FY2027 earnings at ($0.88) EPS, FY2028 earnings at ($1.09) EPS and FY2029 earnings at ($1.47) EPS.

Several other research firms have also weighed in on CLYM. BTIG Research reaffirmed a "buy" rating and issued a $8.00 target price on shares of Climb Bio in a report on Thursday. Wall Street Zen raised shares of Climb Bio from a "sell" rating to a "hold" rating in a report on Monday, October 6th. HC Wainwright started coverage on shares of Climb Bio in a report on Monday, October 13th. They issued a "buy" rating and a $9.00 target price on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Climb Bio in a report on Wednesday, October 8th. Finally, Robert W. Baird started coverage on shares of Climb Bio in a report on Friday, August 15th. They set an "outperform" rating and a $9.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $9.20.

Climb Bio Stock Performance

CLYM opened at $1.93 on Monday. The firm's 50-day simple moving average is $2.10 and its 200-day simple moving average is $1.58. Climb Bio has a twelve month low of $1.05 and a twelve month high of $5.10. The firm has a market cap of $130.78 million, a price-to-earnings ratio of -2.76 and a beta of -0.07.

Climb Bio (NASDAQ:CLYM - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.06.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CLYM. Bank of New York Mellon Corp acquired a new position in Climb Bio during the 1st quarter valued at about $79,000. Peapod Lane Capital LLC acquired a new position in Climb Bio during the 1st quarter valued at about $676,000. TD Asset Management Inc acquired a new stake in shares of Climb Bio in the 1st quarter valued at approximately $109,000. XTX Topco Ltd acquired a new stake in shares of Climb Bio in the 1st quarter valued at approximately $34,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Climb Bio in the 1st quarter valued at approximately $86,000. 69.76% of the stock is currently owned by institutional investors and hedge funds.

Climb Bio Company Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.